Skip to main content

Janux Therapeutics, Inc.

JANX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001817713

No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Janux Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Janux Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Janux Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Campbell David AlanPresident and CEO264,742Jul 31, 20263
RA Capital Healthcare Fund LPDirector, 10% Owner11,750IndirectJun 12, 20261
Ra Capital Management, L.P.Director, 10% Owner11,750IndirectJun 12, 20261
Kolchinsky PeterDirector, 10% Owner11,750IndirectJun 12, 20261
Shah Rajeev M.Director, 10% Owner11,750IndirectJun 12, 20261
RA Capital Nexus Fund II, L.P.Director11,750IndirectJun 12, 20261
Dobmeier EricDirector15,481Jun 12, 20261
Capps Vickie LDirector79,598Jun 12, 20261
Barrett Ronald WDirector11,750Jun 12, 20261
Kung WinstonDirector11,750Jun 12, 20261
Hernday NatashaDirector15,481Jun 12, 20261
Simson JakeDirector11,750Jun 12, 20261
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr75,941Jun 4, 20262
Dobek MariaVice President, Accounting32,270May 13, 20262
Go WilliamChief Medical Officer44,000Feb 4, 20261
Meyer Andrew HollmanChief Business Officer83,095Jan 2, 20264
Winter Charles M.Chief Technical Officer106,321Jan 2, 20261
DiRaimondo ThomasChief Scientific Officer155,825Jan 2, 20261
McIver ZachariahChief Medical Officer52,286Jan 2, 20261
Gujrathi SheilaDirector118,889Jun 13, 20250
McNulty Alana B.Director6,250Jun 13, 20250
Robinson ByronChief Strategy Officer28,000Jan 3, 20250
Lichter Jay10% Owner7,000Oct 24, 20240
Avalon Ventures XI, L.P.10% Owner2,115,373IndirectOct 18, 20240
Avalon BioVentures SPV I, L.P.10% Owner2,115,373IndirectOct 18, 20240
Avalon BioVentures I, LP10% Owner2,115,373IndirectOct 18, 20240
Reardon TigheActing Chief Financial Officer3,340,018IndirectJun 5, 20240
Godfrey WayneChief Medical Officer–Jan 5, 20230
Thompson Peter A.Director231,098IndirectJun 16, 20220
Heller StefanDirector–Jun 16, 20220
Salek-Ardakani ShahramChief Scientific Officer–Jan 5, 20220
OrbiMed Advisors LLCDirector231,098IndirectDec 30, 20210
OrbiMed Genesis GP LLCDirector231,098IndirectDec 30, 20210
OrbiMed Capital GP VIII LLCDirector231,098IndirectDec 30, 20210
OrbiMed Capital GP VII LLCDirector245,898IndirectDec 17, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 17, 2021 (view filing)Dec 161 dayThompson Peter A.DirectorSSale−393.3K$19.07−$7.50M−61.5%245.9K after2 lots
Dec 17, 2021 (view filing)5:13 PM ETDec 161 dayOrbiMed Advisors LLC and 2 othersDirectorSSale−393.3K$19.07−$7.50M−61.5%245.9K after2 lotsDuplicate filing
Dec 23, 2021 (view filing)Dec 212 daysThompson Peter A.DirectorSSale−119.4K$19.00−$2.27M−33.7%234.8K after2 lots
Dec 23, 2021 (view filing)4:13 PM ETDec 212 daysOrbiMed Advisors LLC and 2 othersDirectorSSale−119.4K$19.00−$2.27M−33.7%234.8K after2 lotsDuplicate filing
Dec 30, 2021 (view filing)Dec 291 dayThompson Peter A.DirectorSSale−40.4K$20.30−$820.1K−14.9%231.1K after2 lots
Dec 30, 2021 (view filing)9:00 PM ETDec 291 dayOrbiMed Advisors LLC and 2 othersDirectorSSale−40.4K$20.30−$820.1K−14.9%231.1K after2 lotsDuplicate filing
Jul 21, 2023 (view filing)4:31 PM ETJul 192 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+495.0K$12.46+$6.17M+6.5%8.12M after
Jul 21, 2023 (view filing)4:31 PM ETJul 192 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+503.2K$12.46+$6.27M–503.2K afterDerivative
Nov 13, 2023 (view filing)7:11 PM ETNov 13Same dayAvalon Ventures XI, L.P. and 2 others10% OwnerPPurchase+849.9K$5.87+$4.99MNew position849.9K after
Nov 15, 2023 (view filing)Nov 132 daysLichter JayDirector, 10% OwnerPPurchase+849.9K$5.87+$4.99MNew position849.9K afterDuplicate filing
Nov 15, 2023 (view filing)Nov 132 daysReardon TigheActing Chief Financial OfficerPPurchase+849.9K$5.87+$4.99MNew position849.9K afterDuplicate filing
Mar 6, 2024 (view filing)4:15 PM ETMar 42 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.40M$46.50+$65.0M–1.40M afterDerivative
Jun 5, 2024 (view filing)Jun 32 daysReardon TigheActing Chief Financial OfficerSSale−822.7K$54.75−$45.0M−19.8%3.34M after2 lots
Jun 5, 2024 (view filing)Jun 32 daysLichter JayDirector, 10% OwnerSSale−1.50M$54.75−$82.1M−31.0%3.34M after3 lots
Jun 5, 2024 (view filing)7:19 PM ETJun 32 daysAvalon Ventures XI, L.P. and 2 others10% OwnerSSale−677.3K$54.75−$37.1M−17.2%3.27M after
Jun 5, 2024 (view filing)7:19 PM ETJun 32 daysAvalon Ventures XI, L.P. and 2 others10% OwnerSSale−822.7K$54.75−$45.0M−19.8%3.34M after2 lotsDuplicate filing
Sep 10, 2024 (view filing)5:02 PM ETSep 6-94 daysLichter Jay and 3 others10% OwnerSSale−110.5K$42.01−$4.64M−94.0%7.00K after2 lots
Sep 10, 2024 (view filing)5:02 PM ETSep 64 daysLichter Jay and 3 others10% OwnerSSale−131.6K$42.00−$5.53M−3.9%3.23M after2 lots
Sep 12, 2024 (view filing)8:42 PM ETSep 10-122 daysLichter Jay and 3 others10% OwnerSSale−203.7K$46.89−$9.55M−6.4%2.96M after3 lots
Sep 12, 2024 (view filing)8:42 PM ETSep 10-122 daysLichter Jay and 3 others10% OwnerSSale−247.4K$46.89−$11.6M−7.6%3.02M after6 lots
Sep 27, 2024 (view filing)Sep 27Same dayCampbell David AlanPresident and CEOSSale−25.0K$46.31−$1.16M−7.5%307.1K after3 lots10b5-1
Sep 27, 2024 (view filing)Sep 27Same dayDiRaimondo ThomasChief Scientific OfficerSSale−5.00K$46.35−$231.7K−4.9%97.9K after2 lots10b5-1
Sep 27, 2024 (view filing)Sep 27Same dayMeyer Andrew HollmanChief Business OfficerSSale−50.0K$45.96−$2.30M−42.5%67.6K after
Sep 30, 2024 (view filing)8:49 PM ETSep 26-304 daysLichter Jay and 3 others10% OwnerSSale−140.5K$46.95−$6.60M−95.3%6.89K after6 lots
Sep 30, 2024 (view filing)8:49 PM ETSep 26-274 daysLichter Jay and 3 others10% OwnerSSale−167.3K$46.96−$7.86M−5.5%2.88M after8 lots
Oct 18, 2024 (view filing)6:51 PM ETOct 16-182 daysLichter Jay and 3 others10% OwnerSSale−762.5K$46.34−$35.3M−26.9%2.07M after7 lots
Oct 18, 2024 (view filing)6:51 PM ETOct 16-182 daysLichter Jay and 3 others10% OwnerSSale−910.7K$46.27−$42.1M−30.1%2.12M after10 lots
Oct 22, 2024 (view filing)4:20 PM ETOct 184 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+1.20M$44.75+$53.7M+14.8%9.32M after
Oct 24, 2024 (view filing)Sep 1341 daysLateLichter Jay10% OwnerSSale−3.81K$46.68−$178.1K−35.3%7.00K after
Oct 30, 2024 (view filing)Oct 282 daysCampbell David AlanPresident and CEOSSale−25.0K$53.54−$1.34M−8.1%282.1K after2 lots10b5-1
Nov 27, 2024 (view filing)Nov 252 daysCampbell David AlanPresident and CEOSSale−25.0K$51.59−$1.29M−8.9%257.1K after2 lots10b5-1
Dec 3, 2024 (view filing)Dec 3Same dayCampbell David AlanPresident and CEOSSale−15.0K$67.00−$1.00M−5.8%242.1K after10b5-1
Dec 27, 2024 (view filing)Dec 243 daysCampbell David AlanPresident and CEOSSale−25.0K$56.19−$1.40M−10.3%217.1K after10b5-1
Jan 3, 2025 (view filing)Jan 21 dayMeyer Andrew HollmanChief Business OfficerSSale−13.3K$54.88−$731.8K−14.0%82.1K after5 lots
Jan 8, 2025 (view filing)Jan 71 dayCampbell David AlanPresident and CEOSSale−5.00K$60.00−$300.0K−1.7%293.1K after10b5-1
Feb 5, 2025 (view filing)Feb 32 daysMeyer Andrew HollmanChief Business OfficerSSale−3.33K$42.29−$141.0K−3.9%82.1K after3 lots10b5-1
Mar 5, 2025 (view filing)Mar 32 daysMeyer Andrew HollmanChief Business OfficerSSale−3.33K$32.14−$107.2K−3.9%82.1K after2 lots10b5-1
Mar 7, 2025 (view filing)6:05 PM ETMar 5-72 daysRA Capital Healthcare Fund LP and 4 othersDirector, 10% OwnerPPurchase+824.0K$30.75+$25.3M+8.8%10.1M after4 lots
Apr 23, 2025 (view filing)Apr 212 daysMeyer Andrew HollmanChief Business OfficerSSale−3.33K$30.00−$100.0K−3.9%82.1K after10b5-1
May 2, 2025 (view filing)May 11 dayMeyer Andrew HollmanChief Business OfficerSSale−3.33K$32.03−$106.7K−3.9%82.1K after2 lots10b5-1
Oct 30, 2025 (view filing)Oct 282 daysMeyer Andrew HollmanChief Business OfficerSSale−16.7K$30.06−$500.9K−16.9%82.1K after10b5-1
Nov 14, 2025 (view filing)Nov 14Same dayMeyer Andrew HollmanChief Business OfficerSSale−3.33K$30.00−$100.0K−3.8%85.0K after10b5-1
Dec 3, 2025 (view filing)Dec 12 daysMeyer Andrew HollmanChief Business OfficerSSale−3.33K$32.98−$109.9K−3.8%85.0K after2 lots10b5-1
Jan 2, 2026 (view filing)Jan 2Same dayCampbell David AlanPresident and CEOSSale−8.07K$13.73−$110.8K−2.8%285.0K after
Jan 2, 2026 (view filing)Jan 2Same dayMeyer Andrew HollmanChief Business OfficerSSale−1.88K$13.73−$25.8K−2.2%83.1K after
Jan 2, 2026 (view filing)Jan 2Same dayWinter Charles M.Chief Technical OfficerSSale−2.40K$13.73−$33.0K−3.0%77.7K after
Jan 2, 2026 (view filing)Jan 2Same dayDiRaimondo ThomasChief Scientific OfficerSSale−2.50K$13.73−$34.4K−2.0%124.4K after
Jan 2, 2026 (view filing)Jan 2Same dayDobek MariaVice President, AccountingSSale−1.46K$13.73−$20.1K−8.7%15.4K after
Jan 2, 2026 (view filing)Jan 2Same dayMcIver ZachariahChief Medical OfficerSSale−2.71K$13.73−$37.3K−10.4%23.3K after
May 13, 2026 (view filing)May 112 daysDobek MariaVice President, AccountingSSale−2.04K$14.17−$28.9K−5.9%32.3K after